Episode 1: The Burden of Nash

Overview

In this podcast, AGA Institute’s NASH: Take Action! Steering Committee members talk to global leaders in gastroenterology, hepatology, endocrinology and primary care about the real-world, practical implications of screening, diagnosing and managing people with NAFLD and NASH. In this episode they’ll talk about the prevalence of NAFLD and NASH and their clinical and economic burdens.

Learning Objectives

By the end of this podcast, listeners should be able to:

Understand the prevalence of NAFLD and NASH and their clinical and economic burdens

Key Takeaways

The global burden of NASH is high and increasing across all ages and genders, as is the number of patients affected by NAFLD-related liver cancer, cirrhosis, liver transplantation, and mortality.
NASH is becoming the number one risk factor for cirrhosis, advanced cirrhosis, and liver cancer in women and is already the number one indication for liver transplantation in women and in people ages 54 and older.
Lack of awareness about NAFLD and NASH among patients, care providers, and policymakers remains a major challenge to effectively managing these conditions.

CME

To claim credit, visit AGA University. You will need to create a free account to log in and claim your credit.

This activity is accredited through Sep. 30, 2022.

The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians. The AGA Institute designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

Credits

Hosts: Fasiha Kanwal, MD, Baylor College of Medicine; Kenneth Cusi, MD, University of Florida; Jay Shubrook, DO, Touro University

Guest: Zobair Younossi, MD, President, Medicine Service Line, Inova Health System

Created by: Knighten Health, LLC

Produced and edited by: Nick Jaworksi

Cover art: THOR Design Studio

Disclosures

Fasiha Kanwal discloses no conflicts.

Kenneth Cusi has received research support for the University of Florida as principal investigator from Cirius, Echosens, Inventiva, Novo Nordisk, Poxel and Zydus and is a consultant for Allergan, Arrowhead, Astra-Zeneca, Axcella, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Fractyl, Hanmi, Genentech, Gilead, HighTide, Inventiva, Intercept, Ionis, Janssen, Pfizer, Poxel, Prosciento, Madrigal, and Novo Nordisk.

Jay H. Shubrook has served as an advisor to Sanofi, Eli Lilly, Novo Nordisk, Bayer, and MannKind.

Zobair Younossi has received research funding from or served as a consultant for Gilead Sciences, Intercept, BMS, Novo Nordisk, Viking, Terns, Siemens, Shionogi, AbbVie, Madrigal, Merck, Abbott, Axcella, and Novartis.

Sponsor

American Gastroenterological Association

Funding

This podcast series was supported by an independent medical education grant from Novo Nordisk Inc.